Will delays in treatment jeopardize the population benefit from extending the time window for stroke thrombolysis?
Will delays in treatment jeopardize the population benefit from extending the time window for stroke thrombolysis?
BACKGROUND AND PURPOSE:
Pooled analyses show benefits of intravenous alteplase (recombinant tissue-type plasminogen activator) treatment for acute ischemic stroke up to 4.5 hours after onset despite marketing approval for up to 3 hours. However, the benefit from thrombolysis is critically time-dependent and if extending the time window reduces treatment urgency, this could reduce the population benefit from any extension.
METHODS:
Based on 3830 UK patients registered between 2005 to 2010 in the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Registry (SITS-ISTR), a Monte Carlo simulation was used to model recombinant tissue-type plasminogen activator treatment up to 4·5 hours from onset and assess the impact (numbers surviving with little or no disability) from changes in hospital treatment times associated with this extended time window.
RESULTS:
We observed a significant relation between time remaining to treat and time taken to treat in the UK SITS-ISTR data set after adjustment for censoring. Simulation showed that as this "deadline effect" increases, an extended treatment time window entails that an increasing number of patients are treated at a progressively lower absolute benefit to a point where the population benefit from extending the time window is entirely negated.
CONCLUSIONS:
Despite the benefit for individual patients treated up to 4.5 hours after onset, the population benefit may be reduced or lost altogether if extending the time window results in more patients being treated but at a lower absolute benefit. A universally applied reduction in hospital arrival to treatment times of 8 minutes would confer a population benefit as large as the time window extension.
emergency care, simulation, thrombolysis
2992-2997
Pitt, Martin
754f5149-06d7-461b-8632-9bda2c79095e
Monks, Thomas
fece343c-106d-461d-a1dd-71c1772627ca
Agarwal, Paritosh
4e285931-3144-46f2-a7c8-3247cd965a54
Worthington, David
ab73db70-8d63-4991-b743-c0c2f8ca6c47
Ford, Gary A.
c03a4c65-e4ef-4d39-a8be-dbdc20cfef0b
Lees, Kennedy R.
13c081c8-8b35-4dc8-8b2a-7e88ab714117
Stein, Ken
dba3ca57-81c5-4172-a80e-2b38f61a7cc1
James, Martin A.
b77536bf-9471-436c-a95e-c921e4f90f5a
November 2012
Pitt, Martin
754f5149-06d7-461b-8632-9bda2c79095e
Monks, Thomas
fece343c-106d-461d-a1dd-71c1772627ca
Agarwal, Paritosh
4e285931-3144-46f2-a7c8-3247cd965a54
Worthington, David
ab73db70-8d63-4991-b743-c0c2f8ca6c47
Ford, Gary A.
c03a4c65-e4ef-4d39-a8be-dbdc20cfef0b
Lees, Kennedy R.
13c081c8-8b35-4dc8-8b2a-7e88ab714117
Stein, Ken
dba3ca57-81c5-4172-a80e-2b38f61a7cc1
James, Martin A.
b77536bf-9471-436c-a95e-c921e4f90f5a
Pitt, Martin, Monks, Thomas, Agarwal, Paritosh, Worthington, David, Ford, Gary A., Lees, Kennedy R., Stein, Ken and James, Martin A.
(2012)
Will delays in treatment jeopardize the population benefit from extending the time window for stroke thrombolysis?
Stroke, 43 (11), .
(doi:10.1161/STROKEAHA.111.638650).
(PMID:23010678)
Abstract
BACKGROUND AND PURPOSE:
Pooled analyses show benefits of intravenous alteplase (recombinant tissue-type plasminogen activator) treatment for acute ischemic stroke up to 4.5 hours after onset despite marketing approval for up to 3 hours. However, the benefit from thrombolysis is critically time-dependent and if extending the time window reduces treatment urgency, this could reduce the population benefit from any extension.
METHODS:
Based on 3830 UK patients registered between 2005 to 2010 in the Safe Implementation of Treatments in Stroke-International Stroke Thrombolysis Registry (SITS-ISTR), a Monte Carlo simulation was used to model recombinant tissue-type plasminogen activator treatment up to 4·5 hours from onset and assess the impact (numbers surviving with little or no disability) from changes in hospital treatment times associated with this extended time window.
RESULTS:
We observed a significant relation between time remaining to treat and time taken to treat in the UK SITS-ISTR data set after adjustment for censoring. Simulation showed that as this "deadline effect" increases, an extended treatment time window entails that an increasing number of patients are treated at a progressively lower absolute benefit to a point where the population benefit from extending the time window is entirely negated.
CONCLUSIONS:
Despite the benefit for individual patients treated up to 4.5 hours after onset, the population benefit may be reduced or lost altogether if extending the time window results in more patients being treated but at a lower absolute benefit. A universally applied reduction in hospital arrival to treatment times of 8 minutes would confer a population benefit as large as the time window extension.
This record has no associated files available for download.
More information
e-pub ahead of print date: 25 September 2012
Published date: November 2012
Keywords:
emergency care, simulation, thrombolysis
Organisations:
Faculty of Health Sciences
Identifiers
Local EPrints ID: 367144
URI: http://eprints.soton.ac.uk/id/eprint/367144
ISSN: 0039-2499
PURE UUID: fd770284-512f-4e2f-b753-01d330e24187
Catalogue record
Date deposited: 18 Aug 2014 10:31
Last modified: 14 Mar 2024 17:24
Export record
Altmetrics
Contributors
Author:
Martin Pitt
Author:
Thomas Monks
Author:
Paritosh Agarwal
Author:
David Worthington
Author:
Gary A. Ford
Author:
Kennedy R. Lees
Author:
Ken Stein
Author:
Martin A. James
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics